Effects of Sodium–Glucose Co-Transporter Inhibitors on Individual Clinical Endpoints and Quality of Life
Authors' conclusion
In patients with a broad spectrum of cardiovascular risk factors, SGLTis substantially improve individual hard clinical outcomes and QoL.
Study context
- Population
- Patients with CV risk factors13 randomized controlled trials (RCTs) (Subset A)
- Participants
- 90,413 patients
- Comparison
- SGLTis vs placebo
- Outcome
- Individual hard clinical endpoints (Subset A) and QoL (Subset B)
Methodological detailsSearched PubMed, Embase, Cochrane Library and clinicaltrials.gov up to February 2024
- Searched PubMed, Embase, Cochrane Library and clinicaltrials.gov up to February 2024
Pooled result
As reported in the abstract
Individual hard clinical endpoints (Subset A) · follow-up 2.4 ± 0.3 years
SGLTis vs PlaceboRelative risk (95% CI)P value
All-cause mortality
0.90(0.86–0.94)
P < 0.01CV mortality
0.87(0.82–0.92)
P < 0.01Hospitalization for HF
0.72(0.68–0.76)
P < 0.01HF events
0.72(0.68–0.75)
P < 0.01Hospitalization for any cause
0.91(0.88–0.93)
P < 0.01MI
0.92(0.85–0.99)
P = 0.03Further pooled results
| Outcome | RR (95% CI) | |
|---|---|---|
| All-cause mortality, by subgroupSGLTisvs PlaceboYounger (<65 years) patients | 0.86 (0.81–0.92) | |
| All-cause mortality, by subgroupSGLTisvs PlaceboStudies with less female | 0.84 (0.79–0.90) | |
| MI, sotagliflozin (subgroup)Favourable effect on MI only with sotagliflozin | 0.47 (0.31–0.73) | |
| 0.20.5125Relative risk (log scale) |
Original publication
Effects of Sodium–Glucose Co-Transporter Inhibitors on Individual Clinical Endpoints and Quality of Life. ESC Heart Fail. Published 20 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →